Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Kansas Institute of Research

Neither a doctor nor a teaching hospital

Research payments

$1,350,034

596 payments

Through program year 2025, Kansas Institute of Research is reported as receiving $1,350,034 in research payments, across 596 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $145,304 73
2024 Research $651,735 336
2023 Research $266,108 86
2022 Research $215,929 84
2021 Research $41,941 10
2020 Research $21,414 5
2019 Research $7,604 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $614,924 97 payments
  2. Ipsen Pharma SAS $423,976 398 payments
  3. Averitas Pharma Inc. $170,792 64 payments
  4. Pacira Pharmaceuticals Incorporated $42,726 15 payments
  5. Merz Pharmaceuticals, LLC $41,400 4 payments
  6. GRT US Holding, Inc. $17,906 5 payments
  7. Pfizer Inc. $12,829 4 payments
  8. Eli Lilly and Company $12,008 4 payments
  9. Allergan Inc. $6,064 1 payment
  10. Ipsen Innovation $4,800 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity $373,936 385 payments
  2. Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor $317,080 27 payments
  3. An Interventional Phase III Doubleblind Randomized Controlled Parallelgroup Multisite Clinical Trial Evaluating the Efficacy and Safety of Qutenza in Subjects With Postsurgical Neuropathic Pain $170,792 64 payments
  4. Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine $72,976 22 payments
  5. Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine $58,887 17 payments
  6. Post-stroke Spasticity Referral Tool: Global Inter-Rater Reliability Study $55,960 2 payments
  7. A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity $42,726 15 payments
  8. International, Multicentre, Observational, Prospective, Longitudinal Study to Assess the Effectiveness of AboBoNT-A Injections for Adult Lower Limb Spasticity in a Real Life Cohort (AboLiSh) $25,763 7 payments
  9. A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine $20,700 2 payments
  10. A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine $20,700 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record